Mitochondrial protein interaction landscape of SS-31

Juan D. Chavez[a], Xiaoting Tang[a], Matthew D. Campbell[b], Gustavo Reyes[b], Philip A. Kramer[b], Rudy Stuppard[b] ,Andrew Keller[a], David J. Marcinek[b], and James E. Bruce[a*]

[a]Department of Genome Sciences, University of Washington, Seattle, WA 98105; [b]Department of Radiology, University of Washington, Seattle, WA 98105.

Author contributions: J.D.C., D.J.M., and J.E.B. designed research; J.D.C., M.D.C., G.R., P.A.K., and R.S. performed research; J.D.C, X.T., and A.K. analyzed data; and J.D.C, X.T., M.D.C., G.R., D.J.M., and J.E.B. wrote the paper.

*To whom correspondence should be addressed. Email: jimbruce@uw.edu

Abstract

Mitochondrial dysfunction underlies the etiology of a broad spectrum of diseases including heart disease, cancer, neurodegenerative diseases, and the general aging process. Therapeutics that restore healthy mitochondrial function hold promise for treatment of these conditions. The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown. Reportedly, SS-31 primarily interacts with the phospholipid cardiolipin in the inner mitochondrial membrane. Here we utilize chemical cross-linking with mass spectrometry to identify protein interactors of SS-31 in mitochondria. The SS-31-interacting proteins, all known cardiolipin binders, fall into two groups, those involved in ATP production through the oxidative phosphorylation pathway and those involved in 2-oxoglutarate metabolic processes. Residues cross-linked with SS-31 reveal binding regions that in many cases, are proximal to cardiolipin-protein interacting regions. These results offer the first glimpse of the protein interaction landscape of SS-31 and provide new mechanistic insight relevant to SS-31 mitochondrial therapy.

Introduction

Mitochondria are the power stations of the cell and generate cellular energy in the form of adenosine triphosphate (ATP). ATP is produced by oxidative phosphorylation (OXPHOS) through the mitochondrial electron transport system (ETS) comprising five multi-subunit protein complexes, complex I to complex IV, and complex V, ATP synthase. Mitochondrial dysfunction is associated with many human diseases which can manifest in any organ or tissue, including the nervous system, skeletal and cardiac muscles, kidneys, liver, and endocrine system, and present diverse clinical symptoms [1]. There are few effective treatments for mitochondrial disease as dysfunction of the ETS and OXPHOS for ATP production involves multiple proteins and multiple steps [2]. A conventional therapeutic strategy of targeting a single protein is unlikely to succeed in restoring function in complicated mitochondrial diseases. Another significant challenge for treating mitochondrial dysfunction is the efficient delivery of therapeutic molecules to the mitochondria. Elamipretide (SS-31) is a synthetic tetrapeptide that is a member of an emerging new class of therapeutics that selectively target mitochondria to restore mitochondrial bioenergetics. SS-31 is currently under clinical trials for multiple mitochondrial disorders including aging, mitochondrial genetic disease, ischemia, acute kidney injury, and heart failure [3-5]. SS-31 has shown promising results for treatment of various mitochondrial diseases, however, its mechanism of action remains unclear.

Mitochondria are composed of two membranes, an outer mitochondrial membrane (OMM) and an inner mitochondrial membrane (IMM) which forms invaginations, commonly named cristae. The cristae membranes constitute the backbone platform where mitochondrial respiratory complexes are located and OXPHOS takes place. Cardiolipin (CL), an unusual anionic lipid with two phosphate head groups and four acyl chains, is almost exclusively localized on the IMM [6]. It has long been known that CL has a critical role in bioenergetics, cristae morphology, and assembly of respiratory components into higher order supercomplexes [7, 8]. Bound CL molecules are required for the enzymatic activities and stabilities of both individual protein subunits and protein supercomplexes involved in mitochondrial respiration. For example, CL plays an essential role in the oligomerization of the c-rings and lubrication of its rotation in ATP synthase (CV), which can influence the stability of cristae structure through dimerization[9, 10]; CL acts as glue holding respiratory supercomplexes (CIII and CIV) together and steering their assembly and organization [11, 12]; the binding sites of CL identified close to the proton transfer pathway in CIII and CIV suggest a role of CL in proton uptake through the IMM [13-15]. In the case of the ADP/ATP translocase, ADT, three bound CL molecules securely anchor the carrier protein in the IMM and affect ADP/ATP transport activity [16]. Previous studies have shown that SS-31 peptide can penetrate the OMM and concentrate in the IMM by selectively binding to CL [3-5, 17]. The leading hypothesis is that the alternating aromatic-cationic motif of this synthetic tetrapeptide binds CL via dual interactions, i.e., hydrophobic interaction with acyl chain and electrostatic interactions with anionic phosphate head groups. This specific binding has been validated by fluorescence spectroscopy, isothermal titration calorimetry, and NMR analysis [18, 19]. Though not experimentally demonstrated, it was suggested that binding of SS-31 to CL helps induce tighter curvatures of cristae to stabilize the IMM structure and optimize the organization of respiratory chain supercomplexes for enhanced electron transfer and ATP production [5, 17]. Given the numerous lines of evidence showing SS-31-CL and CL-protein interactions, one could speculate direct interactions may exist between SS-31 and mitochondrial proteins. SS-31-protein interactions could play a direct or synergistic role with CL interactions in mitochondrial structure, cristae morphology, and ATP synthesis. To date, no empirical data exists to demonstrate SS-31 interacts with mitochondrial proteins, and the mechanistic details of how SS-31 modulates and rejuvenates mitochondrial function have remained elusive.

Chemical cross-linking mass spectrometry (XL-MS) has evolved to be a valuable and widely used tool for studying protein structures and interactions [20-23]. Recent development of protein interaction reporter (PIR) based XL-MS technology in our group has further enabled large-scale identification of protein interactions in complex mixtures from living cells [24-26] and isolated functional organelles [27, 28]. Previous studies have shown that SS-31, when added to permeabilized cells or isolated mitochondria, can decrease generation of H_2O_2, increase O_2 consumption and ATP production [18, 19, 29-31]. To investigate the protein interaction landscape of SS-31, we utilized a N-terminal biotinylated form of SS-31 which allows for affinity enrichment of cross-linked SS-31-protein complexes. PIR-based cross-linkers were applied directly to isolated mitochondria incubated with biotinylated SS-31 (bSS-31) to secure a snapshot of protein interactions in their functional state. Subsequent mass spectrometry analysis uncovered the identities of SS-31 protein interactors with topological information. Here, we present the first report of SS-31 protein interaction network, comprising twelve mitochondrial proteins belonging to nine enzymatic complexes. Interestingly, all twelve proteins were previously reported to bind with CL on the IMM and contribute directly and/or indirectly to mitochondrial respiration. These data provide the first evidence of direct interactions between SS-31 and CL-associated proteins. Thus, in addition to effects on IMM structure the interaction between SS-31 and CL may serve to localize SS-31 to the IMM and facilitate its interactions with CL-binding proteins. These SS-31-protein interactions provide new insight into the functional role of SS-31 within mitochondria. Furthermore, our research establishes a novel and general approach to investigate the structural details of protein interactions with therapeutic molecules *in situ*.

Results and Discussion

bSS-31 interactome

SS-31 has been shown to selectively interact with CL, localizing and concentrating the peptide in the IMM [18]. To identify SS-31 protein interaction partners, we utilized an affinity tagged version containing a biotin group on the peptide N-terminus (bSS-31) (**Fig. S1A)** and carried out the experimental workflow illustrated in **Fig. 1**. Importantly, addition of a biotin tag did not affect SS-31 activity. SS-31 has been demonstrated to have no effect on mitochondrial function in young healthy mitochondria, while increasing mitochondrial ATP production and reducing redox stress in aged mouse muscle [30, 32]. Similarly, respiration of mitochondria isolated from old mouse hearts with bSS-31 was significantly higher than those with vehicle controls, while there was no effect of bSS-31 on respiration in mitochondria isolated from young hearts (**Fig. 1**, **Fig. S2)**. bSS-31 also reduced H_2O_2 production in mitochondria from aged mouse hearts (**Fig. 1**, **Fig. S2)**. Isolated mitochondria from aged mouse hearts were incubated with 10 µM bSS-31 for an hour prior to chemical cross-linking with a PIR cross-linker (DP-amide) **(Fig. 1, Fig. S1B**). After cross-linking, mitochondrial proteins were extracted with urea and subjected to a standard tryptic digestion protocol. Peptides cross-linked to bSS-31 were enriched using avidin affinity chromatography and subjected to LC-MS analysis employing two different acquisition methods, ReACT [33] and Mango [34] developed in our lab for the identification of PIR cross-linked peptide pairs. In total we were able to confidently identify 17 non-redundant cross-linked peptide pairs between bSS-31 and 16 Lys residues on 12 different proteins as shown in **Fig. 2 & Table S1**. The bSS-31 cross-linked peptide identifications were repeatedly observed across biological replicate samples originating from four mice. The cross-linked lysine residues are indicated in **Fig. 2**. Interestingly the bSS-31 interacting proteins can be grouped into two broad classes, those involved in ATP production and those utilizing 2-oxoglutarate (**Fig. 2**). Furthermore, each of the 12 proteins is known to directly interact with CL which is important in maintaining the structures and functions for these proteins (**Fig. 2**).

We utilized structural data from the Protein Data Bank (PDB) to localize the cross-linked residues and perform cross-link distance restraint guided molecular docking with bSS-31 using PatchDock [35]. For IDHP and AATM mouse structures were available in the PDB. For the other proteins we employed Clustal Omega [36] to align each mouse protein with homologous structures from other species. Note, all cross-linked Lys residues for the 10 mouse proteins for which no PDB structure exists are conserved in the homologous protein structures from other species. The data have been uploaded into XLinkDB [37] where a table of the cross-linked peptide pairs, interaction network and docked structures can be viewed (http://xlinkdb.gs.washington.edu/xlinkdb/BiotinylatedSS31_Bruce) For each protein docked with bSS-31, the interaction interface with bSS-31 was defined as those amino acid residues within 5 Å of the surface volume encapsulating the atom positions of bSS-31 from the top 10 scoring docked models. We utilized Composition Profiler [38] to compare the amino acid composition of the bSS-31 interfaces with that of the MitoCarta 2 (MC2) database [39]. Statistically-significant differences (P-value <0.05) included residues Asp and Thr which are enriched in bSS-31 interaction interfaces while Leu was depleted as compared with MC2 (**Fig S3**). This observation suggests that electrostatic and hydrogen bonding interactions through Asp and Thr side chains are likely important for bSS-31-protein binding, consistent with the high number of cationic and H-bonding sites within bSS-31, as shown in cross-link-directed bSS-31-protein structural models discussed below.

OXPHOS complexes

OXPHOS complexes generate and maintain the mitochondrial membrane potential (ΔΨ) through the ETS (CI-IV), which powers conversion of ADP to ATP by ATP synthase (CV). The activity of OXPHOS complexes is dependent on cristae morphology and interactions with CL for their proper assembly and function [7]. Excitingly, efforts presented here revealed bSS-31 cross-linked with multiple subunits of the OXPHOS complexes CIII, CIV and CV (**Fig. 2 and 3)** from aged mitochondria. Two subunits of CIII were cross-linked to bSS-31. These included K199 of QCR2 and K83 of QCR6 (PDB: 1sqp [40]). Interestingly, the two bSS-31 interacting subunits of CIII lie on opposite sides of the IMM with QCR2 on the electrochemically negative matrix side and QCR6 located on the electrochemically positive inter-membrane space side (**Fig. 3**). Structural details are presented in **Fig. 3**. CIII functions to reduce cytochrome c transferring electrons from coenzyme Q through the Q-cycle while shuttling protons across the IMM [41]. Structural analysis indicates CIII is normally assembled as a dimer ($CIII_2$), either alone or as part of larger mitochondrial supercomplexes with varying copies of CI and CIV [42]. Each monomer of CIII is comprised of 11 subunits in higher eukaryotes [43]. QCR2 is a core subunit of CIII and is important for its dimerization. QCR6 is a highly acidic subunit that is important for the interaction of CIII with cytochrome c [44]. Reduced cytochrome c carries electrons from CIII to CIV. CIV is the terminal complex of the ETS ultimately transferring electrons from cytochrome c to reduce molecular oxygen to water. bSS-31 was cross-linked to K74 of the CIV subunit NDUA4 which is located in the inter-membrane space. Interestingly, the location of NDUA4 within CIV was only recently resolved as the 14th subunit of the complex [45]. Its location within CIV, precludes CIV dimer formation, suggesting that in contrast to most crystal structures showing CIV assembled as a dimer of 13 subunit complexes, it is instead a 14 subunit monomer [45]. The 14 subunit monomer of CIV is also consistent with structures of the respirasome supercomplex ($CI_1CIII_2CIV_1$) [45]. While not essential for assembly of other CIV subunits, NDUA4 plays a critical role in regulating CIV activity [46]. Monomeric CIV contains multiple CL binding sites that are important for enzymatic activity [47, 48]. Interestingly the PDB structure of human CIV with NDUA4 resolved recently (PDB: 5z62) indicates a CL molecule bound to a deep pocket formed between NDUA4 and cytochrome c oxidative subunits COX2 and COX3, suggesting it may be important for stabilizing the relatively weak interaction of NDUA4 with the rest of CIV [45].

The ETS generated proton gradient and ΔΨ power the phosphorylation of ADP to ATP by CV. Cross-links were detected between bSS-31 and K506 of ATP synthase α-subunit (ATPA) and K480 of ATP synthase β-subunit (ATPB). CV contains three copies each of ATPA and ATPB assembled as a heterohexamer in the F_1 region of the complex on the matrix side of the IMM. There are six nucleotide binding sites located at the ATPA/ATPB interface. Cross-link aided molecular docking localized bSS-31 to ATPB facing the IMM near the ATPA/ATPB interface (**Fig. 3**). The CV dimer is thought to be essential to the formation of cristae by bending the IMM [49]. ATP synthase function depends on CL, which binds specifically, yet intermittently, to the IMM embedded c-ring portion of CV in the F_0 region, acting as a lubricant for rotation of the CV rotor [10, 50, 51]. CV localizes near the tightly curved ends of cristae, where it assembles as rows of dimers stabilizing the IMM curvature [52-54]. Interestingly, isolated CV reconstituted into liposomes self-assemble into rows of dimers inducing membrane curvature [49]. Compartments generated by the membrane folds of cristae allow for pools of highly concentrated protons to drive CV rotation. Beyond the relevance of the dimer structure for ATP production by CV, CV dimers have also been implicated in formation of the mitochondrial permeability transition pore (mPTP) [55]. SS-31 has been shown to improve mitochondrial ATP production as well as inhibit mPTP formation [19, 31].

Prolonged treatment with SS-31 improved function in aged mitochondria, by increasing ATP production, improving flux of the ETS and reducing oxidative stress [32]. The protein interactors in CIII, CIV and CV identified here are central to all of these processes and may help explain the beneficial effects observed with SS-31 treatment.

Creatine kinase and ATP/ADP translocase

Creatine kinase and ADP/ATP translocase are two non-ETS proteins critical for oxidative phosphorylation, shuttling metabolites to ATP synthase (CV) in the form of phosphocreatine (PCr) and ATP (**Fig. 2**). The generation of ATP by OXPHOS is coupled to phosphorylation of creatine (Cr) by creatine kinase that utilizes ATP, transported via the translocase protein, to synthesize PCr, which provides a temporal and special energy buffer for cells [56].

Creatine kinase S-type (KCRS) is a highly symmetric octamer localized in both intermembrane space and cristae space [57]. CL plays an important role for the binding of KCRS to the membranes. It has been suggested that this binding is stabilized by electrostatic interactions between the anionic phosphate head group in CL and a conserved basic motif, consisting of three conserved residues, K408, R418, and K419, in the C-terminal tail of KCRS [58]. The KCRS crystal structure (PDB: 1crk [59]) revealed two identical, opposite flat surfaces of the oligomers, allowing CK binding to two flat bilayer membranes between OMM and IMM, or the two segments of the cristae junctions (**Fig. 2 and 4A**) [59, 60]. The ability of KCRS to bridge two membranes via CL binding is an important factor for maintaining structural stability and integrity of mitochondria. This bridging is also important for the direct use of ATP, exported via the translocase, to phosphorylate Cr. Additionally, KCRS plays a critical role in clustering and enriching CL in the IMM and facilitating co-localization of ADP/ATP translocase into IMM. Our XL-MS results included the identification of bSS-31 interaction with KCRS at K230 (**Fig. 4A**). Superimposition of top ten molecular docking results localized bSS-31 peptide in the inner membrane space proximal to CL binding regions as displayed in blue cloud in **Fig. 4A**, consistent with KCRS binding CL and CL interaction with SS-31.

ADP/ATP translocase (ADT), a transmembrane protein located in the IMM, is a carrier protein for importing ADP from the cytosol and exporting ATP from the mitochondrial matrix through cycling between cytoplasmic-open and matrix-open states (c-state and m-state) [61]. While the inhibitor carboxyatractyloside (CATR) locked ADT c-state crystal structure (PDB: 2c3e) [62] has been available for over a decade, better understanding of the mechanism of ADT for the full transport cycle became possible only recently with resolved crystal structure of bongkrekic acid (BKA) inhibitor locked ADT in m-state (PDB: 6gci) [63]. The six tilted transmembrane α-helices form a bucket-shaped cavity which opens to the intermembrane space (c-state) (**Fig. 4B** top) or the matrix space (m-state) (**Fig. 4B** bottom). Several CL molecules were found in the crystal structures, attached surrounding the bucket (**Fig 4B**). CL molecules tightly bind through several hydrogen bonds and electrostatic interactions to act as an inter-domain bridge stabilizing ADT in the membranes [63]. The adenine nucleotide binding sites are found in the water-filled central cavity with the phosphate groups bound to K23, R80, R280; the adenine ring bound with Y187 via aromatic stacking; hydrophobic interactions with G183 and I184, and hydrogen bonding with S228 [61]. Our PIR cross-linking experiments identified ADT1, an isoform abundantly expressed in the heart, with two lysine residues (K33 and K272) cross-linked with bSS-31. The top ten molecular docking models produced using distance constraints from both lysine residues placed bSS-31 (shown in blue cloud) within the water-filled cavity in the intermembrane or matrix face of the translocase in either c- or m-state structures, respectively (**Fig. 4B**). Additionally, lysine residue K272 appears more likely to be

cross-linked in the m-state as it appears on the matrix side of the protein in either c- or m-states. Moreover, both lysine residues K33 and K272 are involved in salt bridge interactions in the c-state with D232 and E265, respectively, and are therefore less likely to be cross-linker reactive in this state (**Supplemental Video 1**). Finally, in the top cross-link-directed docked bSS-31-ADT1 m-state model, D232 forms a salt bridge with the bSS-31 Arg residue, and thus, would be unavailable for salt bridge formation with K33 that is important for c-state stabilization [63]. Moreover, this model also locates the bSS-31 dimethyl tyrosine residue proximal to Y187 and thus, aromatic stacking analogous to adenine ring interactions may stabilize bSS-31 in this m-state model as well. Importantly, ADT was recently identified to support two distinct and competing transport modes involving ADP/ATP exchange and proton leak and thus, ADT connects coupled and uncoupled energy conversion mechanisms in mitochondria, respectively [64]. While it is not possible to conclusively determine which or if both states bind bSS-31 from these data, an important conclusion that can be made is that bSS-31 binds within the ADT channel and thus could affect either ADP/ATP exchange or proton leak. Interestingly, bSS-31 binding to the ADT channel yet not functioning as an ADT inhibitor opens the possibility of therapeutic alteration of the balance of conformational states, potentially modulating proton leak and ADP/ATP exchange. The mechanism of proton leak through ADT is dependent on electrostatic interactions of the positively charged substrate binding site with a fatty acid co-factor, and competes with nucleotide transport through ADT [64]. The ability of bSS-31 to interact directly with ADT and lipids suggest it could modulate the fatty acid-ADT interaction, and thereby proton leakage through ADT. Since favorable SS-31 pharmacological effects on mitochondrial function include increased ATP production and decreased proton leak [3], bSS-31 interaction with ADT in mitochondria identified in this work may be an important mediator of these beneficial effects.

Trifunctional enzyme

The mitochondrial trifunctional enzyme is a hetero-oligomeric complex localized on the IMM that catalyzes the latter three reactions of fatty acid β-oxidation for very long chain fatty acids. The trifunctional enzyme consists of the α-subunit (ECHA) which contains 2-enoyl-CoA hydratase (ECH), and 3-hydroxyacyl-CoA dehydrogenase (HAD) activities, and the β-subunit (ECHB) containing 3-ketothiolase (KT) activity. Within mitochondria, the trifunctional enzyme is thought to primarily be assembled as an $\alpha_2\beta_2$ hetero-tetramer. Recently, structural models for the human trifunctional enzyme have been determined by cryo-EM [65] and x-ray crystallography [66] both highlighting important structural differences between the mammalian mitochondrial trifunctional enzyme and the structures of bacterial orthologs [67, 68]. Both structures for the $\alpha_2\beta_2$ mitochondrial trifunctional enzyme reveal a curved structure to the complex where the concave surface is important for interaction with the IMM [65, 66]. Beyond functioning in fatty acid β-oxidation, ECHA also functions to remodel CL via monolysocardiolipin acyltransferase activity [69]. The α-subunit of the mitochondrial trifunctional enzyme (ECHA) was cross-linked at K505 and K644 to bSS-31. Both of these residues exist on the concave side of the complex near the inner mitochondrial membrane where cardiolipin resides (PDB: 6dv2) (**Fig. 5**). Cross-linking distance constraint guided docking of bSS-31 with ECHA places bSS-31 into a substrate channel in ECHA near the HAD active side, proposed to be important for cardiolipin remodeling [66] (**Fig. 5**).

2-oxoglutarate enzymes

The metabolite 2-oxoglutarate (aka α-ketoglutarate, 2-OG) is a key intermediate of the tricarboxylic acid (TCA) cycle, building block for amino acids and nitrogen transporter. Due to its involvement in both carbon and nitrogen metabolism and multiple signaling pathways, 2-OG has been suggested to act as a master regulator metabolite [70]. One example of this is highlighted by the discovery that 2-OG can extend the lifespan of *Caenorhabditis elegans* by inhibiting ATP synthase and target of rapamycin (TOR) downstream [71]. 2-OG also plays a key role in hypoxia signaling serving as a substrate for prolylhydroxylase (PHD) enzymes which regulate the stability of hypoxia inducible factors (HIF) transcription factors [72, 73]. Interestingly, we identified bSS-31 cross-linked with multiple lysine sites across four key proteins including isocitrate dehydrogenase, 2-OG dehydrogenase (ODO1), dihydrolipoyllysine-residue succinyltransferase component of 2-OG dehydrogenase complex (ODO2) and aspartate aminotransferase (AATM), all of which produce or utilize 2-OG in their reactions. Excitingly these interactions suggest a potential role for SS-31 in 2-OG signaling.

Isocitrate dehydrogenase catalyzes the decarboxylation of isocitrate forming 2-OG and carbon dioxide. There are three types of isocitrate dehydrogenase in mammals, IDH1, IDH2 and IDH3, which differ in structure, function and subcellular localization [74]. IDH1 and IDH2 are $NADP^+$-dependent enzymes that catalyze reversible reactions and are localized in the cytosol and mitochondria respectively [74]. IDH3 is the NAD^+-dependent form, localized to the mitochondrial matrix functioning primarily in energy production in the TCA cycle where it catalyzes an irreversible reaction and is allosterically regulated by a number of cofactors [74]. The mitochondrial localized $NADP^+$-dependent IDH2 (aka IDHP) also functions in the TCA cycle but has additional roles in supplying NADPH used in redox homeostasis and fatty acid metabolism [75]. This places IDHP at a critical crossroad, regulating energy production through the TCA cycle, maintaining the mitochondrial pool of NADPH needed for the glutathione antioxidant system and producing 2-OG utilized by PHD proteins in HIF1α signaling. Interestingly, IDHP can also interact with CL containing membranes that can induce a conformational change in IDHP regulating its enzymatic activity [76]. Cross-links were identified between bSS-31 and K180, K272 and K360 of IDHP. Docking of bSS31 with the PDB structure of IDHP (5h3f) results in localization of bSS-31 to a groove between the large and small domains of IDHP near the isocitrate binding pocket (**Fig. 6A&B**). Electrostatic repulsion between positively charged Lys residues located in the large domain (K127, K129, K130 and K133) and the small domain (K256) has been suggested to play an important role in IDHP activity by widening the cleft between the domains [77] (**Fig. 6B**). Neutralization of the charged residues by acetylation or mutation on these Lys residues results in a narrower cleft, smaller isocitrate binding pocket and lower enzymatic activity [77]. A number of acidic residues surround the bSS-31 interface, potentially participating in electrostatic interactions with bSS-31 (**Fig. 6B**). It is possible that when SS-31 interacts with IDHP, the positive charges in SS-31 would also play a role in widening the cleft between the domains, potentially impacting IDHP activity.

Catalyzing the rate limiting fourth step of the TCA cycle is 2-OG dehydrogenase complex (2-OGDHC), which utilizes thiamine pyrophosphate (TPP) as a cofactor and reduces NAD^+ to NADH during the conversion of 2-OG to succinyl-CoA and CO_2. The 2-OGDHC is a large multi-protein assembly (~2 MDa) localized on the IMM comprising multiple copies of three enzymatic components E1 (ODO1), E2 (ODO2) and E3 (dihydrolipoyl dehydrogenase, DLDH) and sharing similar assembly with the pyruvate dehydrogenase complex (PDH) and the branched chain 2-oxoacid dehydrogenase complex (BCKDH). There are no high-resolution structural models available for any components of the mammalian 2-OGDHC. Experimental evidence from multiple sources including genetic mutational, limited proteolysis and electron microscopy

indicate the 2-OGDHC is composed of 24 E2 subunits assembled into a cubic core with varying numbers of E1 and E3 subunits bound to the periphery of the core [78]. The activity of the 2-OGDHC is tightly regulated, being inhibited by ATP, NADH and succinyl-CoA, intertwining its function with that of the OXPHOS complexes. Under some conditions it can also be a primary source of mitochondrial ROS production producing superoxide and hydrogen peroxide at much higher rates than complex I, which is often implicated as the primary source of mitochondrial ROS [79]. The E3 component of 2-OGDHC produces ROS in the form of H_2O_2 and superoxide radicals when electrons from the $FADH_2$ transfer to molecular oxygen. Furthermore, very reactive and damaging lipoate thiyl radicals can form in the E2 component as a result of reaction with a FADH semiquinone [79]. We identified cross-links between bSS-31 and K582 of ODO1 (E1) and K278 of ODO2 (E2) **Fig 6C**. Interestingly, CL has been shown to be important for the stability of the 2-OGDHC [80].

The mitochondrial aspartate aminotransferase (AATM) catalyzes the reversible reaction of aspartate and 2-OG to glutamate and oxaloacetate. AATM is a key enzyme linking amino acid and carbohydrate metabolism by providing a carbon source (2-OG) to the TCA cycle as well as nitrogen for the synthesis of non-essential amino acids and nucleotides [81]. Beyond its canonical function, mitochondrial AATM also functions as kynurenine aminotransferase as well as a transporter for long chain fatty acids [81, 82]. AATM also interacts directly with the cardiolipin containing liposomes, the inner-mitochondrial membrane as well as the 2-OGDHC [83, 84]. We identified a cross-link between bSS-31 and K159 of AATM. Cross-link guided docking places bSS-31 near the oxaloacetate binding pocket in the PDB structure 3PDB **Fig 6D**. This is on the opposite side of AATM from the LCFA binding pocket, colored as blue space filled residues in **Fig 6D**.

Overall the enzymes IDHP, ODO1, ODO2 and AATM function in closely connected biological pathways related to regulation of 2-OG levels, mitochondrial redox homeostasis and HIF1-α signaling in addition to key metabolic pathways. The specific interactions detected between these proteins and bSS-31 suggest a possible role for SS-31 to influence this nexus of mitochondrial function.

Previous efforts to elucidate SS-31 mechanisms have suggested that beneficial therapeutic effects arise from SS-31 interaction with CL. While CL binding may be the primary impact of SS-31 treatment, the present work resulted in identification of the first set of SS-31 interacting proteins from intact, functional mitochondria using PIR XL-MS. These results provide new insight and new opportunities to better understand the molecular actions of this mitochondrial targeted therapeutic. This set of 12 proteins are all part of a larger energy transfer system for mitochondrial ATP production through the OXPHOS pathway. Four of the proteins are directly involved with 2-OG metabolism and signaling which regulates mitochondrial metabolism, redox homeostasis, and cellular response to hypoxia. Importantly each of the SS-31 interacting proteins also interact with CL, which impacts their structure and function. This observation presents the possibility that SS-31 concentrates in the IMM by interacting with CL, facilitating its interactions with components of the OXPHOS and 2-OG signaling pathways. Numerous studies have demonstrated the beneficial effects of SS-31 to restore healthy mitochondrial function, increase ATP production, and reduce mitochondrial redox stress. Beyond identifying protein interaction partners, the XL-MS data provide structural information, in terms of distance restraints, that were used to localize bSS-31 interacting regions on these proteins. Knowledge of these protein interactors lays the foundation for follow up functional studies to evaluate the significance of these interactions. As a general method, employing affinity tagged drugs with XL-MS should be extensible to investigate the interaction landscapes of therapeutic molecules in complex biological samples such as organelles, cells and tissues.

Materials and Methods

Animal husbandry

This study was reviewed and approved by the University of Washington Institutional Animal Care and Use Committee. Male, 36-37 month old CB6F1 (BL/6: BalbC) mice were received from the National Institute of Aging aged mouse colony. All mice were maintained at 21°C on a 14/10 light/dark cycle and given standard mouse chow and water ad libitum with no deviation prior to or after experimental procedures. Animals were sacrificed by cervical dislocation with no anesthetic.

Extraction of tissue, mitochondrial isolation and SS-31 treatment

On day of animal sacrifice, the heart (120-150 mg wet weight) was resected. The whole heart was homogenized on ice in a glass Dounce homogenizer in 2 mL of ice-cold respiration buffer (RB, 1 mM EGTA, 5 mM MgCl2, 105 mM K-MES, 30 mM KCl, 10 mM KH_2PO_4, pH 7.1). The homogenates were centrifuged for 10 min at 800 × g at 4 °C. The supernatants were collected and centrifuged for 15 min at 8,000–10,000 × g at 4 °C. After the removal of supernatant, the pellet was resuspended in isolation medium. The pellet was centrifuged for 15 min at 8,000–10,000 × g at 4 °C and was resuspended in isolation medium. Mitochondrial pellets were separated into new centrifuge tubes and diluted with 200 µL RB, 10 mM Pyruvate, and 2 mM Malate. Either elamipretide or 2 µL saline was added to the mitochondria and incubated for 1 hour at room temperature with mild rocking.

Ex Vivo Mitochondrial Respiration and H_2O_2 Production

In a parallel experiment, mitochondria were isolated from young (5-7 month-old) and old (36-37 month old) mouse hearts as described above either in the presence or absence of 10 µM bSS-31. Approximately 100 µg mitochondrial homogenate was used in the 2 mL chamber of an Oxygraph 2K dual respirometer/fluorometer (Oroboros Instruments, Innsbruck, Austria) at 37°C and stirred gently during substrate and inhibitor titrations. Leak respiration was measured by adding 5 mM pyruvate, 2 mM malate, and 10 mM glutamate. Stimulation with 2.5 mM ADP induced state 3 respiration followed by 10 mM succinate. Cytochrome C (6 mM) was added to stimulate maximal state 3 respiration. The rate of maximal uncoupled flux through the ETS was measured by adding 1 µM FCCP. Complex II activity was measured using 0.5 µM rotenone to inhibit complex I followed by complete mitochondrial respiration inhibition by 2.5 µM Antimycin A. The non-mitochondrial rate of oxygen consumption was subtracted from all measured functional parameters before reporting final values. H_2O_2 emission was measured in parallel with respiration using amplex red (10 mM) and HRP (0.1 U/mL).

Cross-linker synthesis

The protein interaction reporter (PIR) cross-linker amide-DP-NHP was synthesized by solid phase peptide synthesis using a CEM Liberty Lite peptide synthesizer. Amino acids were coupled to amide-Rink resin in the following order: biotin-Lys, Fmoc-Lys(Fmoc), Fmoc-Pro, Fmoc-Asp, succinic anhydride. The N-hydroxyphthalamide (NHP) ester of trifluoroacetic acid (TFA) was synthesized by dissolving 5.86 g of NHP in 20 mL of TFA anhydride in a 50 mL round bottom flask. The reaction was allowed to proceed for 1.5 h under a dry N_2 atmosphere with constant mixing via magnetic stir bar. After 1.5 h the mixture was dried under vacuum to obtain a white crystalline solid (TFA-NHP). The cross-linker (0.5 mmoles of peptide on resin) was esterified by reacting with a 12-fold molar excess of TFA-NHP in 10 mL of dry pyridine for 20

min at room temperature with constant mixing. The reaction mixture was transferred to a Bio-Rad poly prep column and the liquid was filtered away. The resin containing the esterified peptide was washed extensively with a total of 60 mL dimethyl formamide (DMF) followed by 60 mL of dichloromethane (DCM). The cross-linker was cleaved from the resin by incubation with 5 mL of 95% TFA, 5% DCM for 3 h at room temperature with constant mixing. The cross-linker was precipitated by adding the cleavage solution to ice cold diethyl ether at a ratio of 1:15 by volume. The cross-linker was pelleted by centrifugation at 3400 g for 30 min at 4°C. The cross-linker pellet was washed by resuspending the pellet in 10 mL of fresh ice cold diethyl ether and repeating the centrifugation step. The cross-linker pellet was then dried by vacuum centrifugation and weighed. The cross-linker was dissolved in DMSO to a concentration of 270 mM, aliquoted and stored at -80°C until used.

Cross-linking reaction

The cross-linker amide-DP-NHP was added at a final concentration of 10 mM (from a 270 mM stock solution) to mitochondria incubated with bSS-31. The reaction mixture was mixed at 800 rpm at room temperature for 30 min. A total of 5 cross-linked samples were generated including 4 biological replicates of mouse heart mitochondria incubated with bSS-31 and a negative control sample to which no bSS-31 was added. After cross-linking the samples were frozen at -80°C.

Cross-linked mitochondrial sample preparation

Cross-linked mitochondrial samples were lysed with 8 M urea in 0.1 M NH$_4$HCO$_3$. The sample was kept on ice and sonicated with a GE 130 ultrasonic processor using 5 cycles of 5 s pulses at an amplitude of 40. The total protein concentration was measured using the Pierce Coomassie Plus Bradfrod protein assay. Protein disulfide bonds were reduced with 5 mM TCEP for 30 min followed by alkylation of thiol groups with 10 mM iodoacetamide for 30 min. Samples were diluted 10-fold with 0.1 M NH$_4$HCO$_3$ and digested with a 1:200 ratio of trypsin to protein at 37°C overnight. After digestion samples were acidified by adding trifluoroacetic acid (TFA) to a final concentration of 1%. Acidified samples were desalted using Waters C18 Sep Pak cartridges and associated vacuum manifold. Samples were passed through the cartridge at a flow rate of 1 mL/min, followed by 3 mL washes of water containing 0.1% TFA. Peptides were eluted from the Sep Pak cartridge with 1 mL of 80% acetonitrile, 20% water, 0.1% TFA. Desalted samples were concentrated by vacuum centrifugation using a Genevac EZ-2 system. Dried samples were reconstituted in 0.5 mL of 0.1 M NH$_4$HCO$_3$ and adjusted to pH 8 with 1.5 M NaOH. 100 uL of 50% UltraLink monomeric avidin slurry was added to the sample and incubated with constant mixing for 30 min at room temperature. The monomeric avidin resin was washed 5 times with 3 mL of 0.1 M NH$_4$HCO$_3$ followed by elution of bound peptides with 2 additions of 0.5 mL of 70% acetonitrile, 0.5% formic acid, each with 5 min incubation. The eluate fractions were pooled and concentrated by vacuum centrifugation. The biotin enriched sample was reconstituted in 30 uL of 0.1% formic acid in water and subjected to LC-MS analysis as described below.

LC-MS analysis of cross-linked peptide pairs

Samples were analyzed by LC-MS using two methods developed for analysis of cross-linked peptide pairs, namely ReACT [33] and Mango [34]. ReACT analysis was carried out on a Velos-FTICR mass spectrometer coupled with a Waters nanoAcquity UPLC. Peptides were fractionated by reversed-phase liquid chromatography by first loading the sample (5 µL injection) onto a trapping column (3 cm x 100 um i.d.) packed with Reprosil C8 beads (Dr. Maisch) using a flow rate of 2 µL/min of 98% solvent A (water, 0.1%

formic acid) and 2% solvent B (acetonitrile, 0.1% formic acid). After trapping peptides were separated over an analytical column (60 cm x 75 um) maintained at 45°C, packed with Reprosil C8 stationary phase using a flow rate of 300 nL/min and applying a binary gradient of 90% solvent A / 2% solvent B to 60% solvent A / 40% solvent B over 120 min followed by a wash cycle consisting of 20% solvent A / 80% solvent B for 20 min and a re-equilibration period consisting of 98% solvent A / 2% solvent B for 20 min. Eluting peptides were ionized by electrospray ionization (ESI) by applying a voltage of 2.6 kV to a laser pulled spray tip at the end of the chromatography column. MS1 analysis (500-2000 m/z) was performed in the ICR cell with a resolving power setting of 50K at 400 m/z, and an automatic gain control (AGC) setting of 5E5. The most abundant precursor ion with a charge state ≥ 4 was selected for MS2 using an isolation window of 3 m/z and a normalized collision energy (NCE) of 25. Fragment ions were analyzed in the ICR cell using a resolving power setting of 12.5K at 400 m/z and an AGC setting of 2E5. MS2 spectra were searched in real-time for fragment ions that satisfy the expected PIR mass relationship (mass peptide 1 + mass peptide 2 + mass reporter = mass precursor) within a 20 ppm mass error tolerance. If satisfied the two released peptide ions were sequentially analyzed by MS3 in the Velos dual ion trap mass analyzer where they were isolated with a 3.0 m/z isolation window and fragmented with a NCE of 35 using an AGC setting of 5E4.

Samples were analyzed by Mango using a Thermo Q-exactive plus mass spectrometer coupled with a Thermo Easy nLC. 5 µL of sample was injected into the nLC system where it was loaded onto a trapping column (3 cm x 100 um i.d.) packed with Reprosil C8 beads (Dr. Maisch) using a flow rate of 2 µL/min of solvent A. After trapping peptides were separated over an analytical column (60 cm x 75 um) maintained at 45°C, packed with Reprosil C8 stationary phase using a flow rate of 300 nL/min by applying the same binary gradient described for the ReACT analysis above. Eluting peptides were ionized by electrospray ionization (ESI) by applying a voltage of 2.6 kV to a laser pulled spray tip at the end of the chromatography column. MS1 analysis (400-2000 m/z) was performed in the orbitrap mass analyzer using a resolving power setting of 70K at 200 m/z and an ACG value of 1E6. This was followed by MS2 on the 5 most abundant precursor ions with charge states ≥ 4 using a 3 m/z isolation window, a resolving power setting of 70K at 200 m/z and an ACG value of 5E4.

Data analysis

LC-MS data files in .RAW format were converted to .mzXML format using the ReADW tool in the Trans Proteomic Pipeline software suite [85]. Comet [86] was used to search the .mzXML files against the Mitocarta 2 database [39] containing both forward and reverse protein sequences (2084 total sequences) along with the addition of the sequence for bSS-31 (Biotin-D-Arg-dimethyl Tyr-Lys-Phe-NH2). Due to the presence of non-canonical amino acids the bSS-31 sequence was entered using the following single letter amino acid sequence BJKZ. Within the Comet parameters file the mass of B (Biotin-D-Arg) was set to 382.17926 Da, the mass of J (dimethyl Tyr) was set to 191.094629 Da and the mass of Z (amidated Phe) was set to 146.084399 Da. Additional Comet parameters used for searching ReACT data included; a peptide mass tolerance of 20 ppm, allowance of -1/0/1/2/3 ^{13}C offsets, trypsin as the digesting enzyme considering only fully tryptic sequences with up to 5 missed cleavage sites. Oxidation of Met (15.9949 Da) was included as a variable modification while the cross-linker stump mass modification on Lys (197.032422 Da) was included as a required modification at any position within the peptide sequence except for the C-terminus, MS3 spectra were searched using a 1.0005 Da tolerance on the fragment ions with a bin offset of 0.4. Comet parameters used for Mango data were the same except that the Mango

search parameter was set to 1, MS2 spectra were searched and a 0.02 Da tolerance with a 0.0 bin offset were used for fragment ions.

Validation of bSS-31 fragmentation spectrum

Ten µL of 10.6 mM bSS-31 in 18.2 MΩ H_2O was transferred to a 1.5 mL tube. 90 µL of 170 mM Na_2HPO_4 pH 8.0 was added. This was followed by addition of 1.11 µL of 270 mM DP-amide cross-linker stock solution in DMSO resulting in a 3 mM final cross-linker concentration. The reaction was carried out at room temperature for 1 h with shaking 1400 rpm. The sample was then acidified to 1 % TFA by volume. The sample was then desalted using a 50 mg size C18 Sep-Pak column. After loading the sample onto the Sep-Pak the peptides were washed with 3 additions of 1 mL H_2O/0.1% TFA. The sample was then eluted from the Sep-Pak column with 1 mL 50% ACN/ 2% CH_3COOH and analyzed by direct infusion MS with the Velos-FTICR mass spectrometer. SpectraST v 5.0 was used to search fragmentation spectra generated by ReACT against a spectral library of the cross-linker modified bSS31. Fragmentation spectra assigned as bSS-31 cross-links were required to contain the accurate mass of the DP stump modified bSS-31 (Fig. S1C) and have a SpectraST assigned p-value of less than 0.1.

Molecular docking

A molecular model for bSS-31 was generated using Avogadro (v. 1.2.0) utilizing a molecular mechanics conformer search of 1000 conformers followed by geometric optimization. PatchDock [35] was used to dock the model of bSS-31 with structural models in the PDB for bSS-31 interacting proteins (AATM = PDB: 3pdb, ADT c-state = PDB:2c3e, ADT m-state = PDB: 6gci, ATPA/ATPB = PDB: 5ARA, QCR2/QCR6 = PDB: 1sqp, NDUA4 = PDB: 5z62, ECHA = PDB: 6dv2, IDHP = PDB: 5h3f, KCRS = PDB: 1crk). Clustal Omega [36] was used to align each mouse protein with homologous structures from other species. For each protein, the top 10 scoring docked models from PatchDock were downloaded and the interaction interface with bSS-31 was defined as those amino acid residues within 5 Å of the surface volume encapsulating the atom positions of bSS-31.

Figure Legends

Figure 1 - Experimental overview. Mice (total of 4) strain CB6F1 (BALB/cBy X C57BL/6) were euthanized by cervical dislocation. Hearts were excised and processed to isolate mitochondria. Isolated mitochondria were treated with 10 µM biotin SS-31 (bSS-31, blue rectangle with yellow triangle) for 1 h. Oxygen consumption rates and H_2O_2 production were monitored to evaluate the functional impact of bSS-31 (**Fig. S2**). Mitochondria were cross-linked with the PIR cross-linker DP-NHP (grey rectangle with orange stars). Protein was extracted using 8 M urea and digested with trypsin. Enrichment for peptides containing bSS-31 was performed with immobilized monomeric avidin. Peptide samples were analyzed by LC-MS to identify the interactome network for bSS-31 and structural analysis was performed using cross-link distance restraint guided molecular docking.

Figure 2 – SS-31 interactome. **A)** Nodes represented by colored circles indicate the 12 proteins cross-linked to bSS-31. UniProt identifiers are labeled on the nodes along with the lysine residues that were identified as cross-linked to bSS-31. All 12 proteins are known to interact with cardiolipin (CL, red). The proteins are grouped into two major classes: ATP processes (upper light blue area) and 2-oxogluterate

processes (lower light purple area). **B)** Schematic representation of SS-31 peptide cross-linked proteins within the mitochondria. These proteins include creatine kinase (KCRS), ADP/ATP translocase (ADT1), complex III (CIII) subunits QCR2 and QCR6, complex IV (CIV) subunit NDUA4, complex V (CV) subunits ATPA and ATPB, trifunctional enzyme subunit (ECHA), aspartate amino transferase (AATM), isocitrate dehydrogenase (IDHP) and 2-oxogluterate dehydrogenase complex subunits ODO1 and ODO2. bSS-31 peptide is represented by a blue rectangle with yellow triangle.

Figure 3 - Structural view of bSS-31 peptide interaction with OXPHOS complexes CIII, CIV, and CV with inset showing zoomed view of binding structure. Distance constraints of 0-35 Å between the α-carbon of K3 of bSS-31 and the α-carbon of cross-linked lysine were used in molecular docking. Proteins are shown in cartoon view. Top ten molecular docking results for bSS-31 were included as shown in superimposed semi-transparent blue surface view with the top one dock position of bSS-31 shown in blue ball-and-stick representation. CL and CL binding residues are shown in magenta ball-and-stick and space fill representation, respectively. Cross-linked lysines are shown in green spheres. Interactive versions of the structures can be viewed at http://xlinkdb.gs.washington.edu/xlinkdb/BiotinylatedSS31_Bruce.

Figure 4 - Structural view of bSS-31 peptide interaction of KCRS and ADT. Distance constraints of 0-35 Å between the α-carbon of K3 of bSS-31 and the α-carbon of cross-linked lysine were used in molecular docking. The top 10 docking results are selected to show the ranges of bSS-31 positions in semi-transparent blue surface view with the first docking position displayed in blue ball-and-stick view. A) A side view of octameric KCRS (PDB: 1crk) bridging outer and inner membrane of mitochondria is shown in cartoon representation in left. Shown in right is monomeric chain A in ribbon view with CL binding residues, K408, R418, and K419, in magenta space-filled balls, and cross-linked residue K230 in green spheres. B) Structural representation of b-SS31 and ADT interaction for both CATR-locked c-state (PDB: 2c3e) (top) and BKA-locked m-state (PDB: 6gci) (bottom). Cross-linked lysines K33 and K272 are shown in green spheres and CL is shown in magenta ball-and-stick. The substrate binding sites, K23, R80, R280, Y187, G183, I184, and S228, are shown in red spheres. Interactive versions of the structures can be viewed at http://xlinkdb.gs.washington.edu/xlinkdb/BiotinylatedSS31_Bruce.

 Figure 5 - Structural view of bSS-31 interaction with ECHA. Distance constraints of 0-35 Å between the α-carbon of K3 of bSS-31 and the α-carbon of cross-linked lysine residues K644 and K505 of PDB structure 6dv2 were used in molecular docking. The top 10 docking results are selected to show the ranges of bSS-31 positions in semi-transparent blue surface view with the first docking position displayed in blue ball-and-stick view. The cross-linked Lys residues on ECHA are shown as green space filled residues. The HAD active site residues proposed to be important for cardiolipin remodeling (S477, H498, E510, T548) are shown as red space filled residues. Interactive versions of the structures can be viewed at http://xlinkdb.gs.washington.edu/xlinkdb/BiotinylatedSS31_Bruce.

Figure 6 - SS-31 interaction with 2-oxoglutarate enzymes. **A)** bSS-31 interaction with IDHP (PDB 5h3f) indicated as a homodimer with the $IDHP_a$ chain shown as a green ribbon and the $IDHP_b$ chain in grey. Lysine residues cross-linked to bSS-31 are displayed as green space filled residues and are labeled with subscript "a" or "b" to indicate which IDHP monomer they are on. bSS-31 (blue ball and stick structure) was docked onto the a-subunit using distance restraints for K180 and K360 from the a-subunit and K272 from the b-subunit. The volume encompassing the positions of bSS-31 from the top 10 docking results is displayed as a semi-transparent blue surface. **B)** View of the bSS-31 interaction interface highlighting surrounding acidic residues (red) and Lys residues (cyan) which are important in maintaining the groove

between the large and small domains of IDHP [77]. **C)** Schematic representation of the 2-oxoglutarate dehydrogenase complex (2-OGDHC). bSS-31 was identified as cross-linked to ODO1 a component of the E1 of 2-OGDHC and ODO2 a component of the E2 portion of 2-OGDHC. **D)** bSS-31 interaction with AATM (PDB 3pdb) shown as a homodimer with the a-chain in teal and the b-chain in grey. Lysine K159 (green space filled residue) of the a-chain was used to dock bSS-31 into the structure. The volume encompassing the positions of bSS-31 from the top 10 docking results is displayed as a semi-transparent blue surface. Interactive versions of the structures can be viewed at http://xlinkdb.gs.washington.edu/xlinkdb/BiotinylatedSS31_Bruce.

Supplemental Figure Legends

 Fig S1 – Structures of biotin SS-31 and PIR cross-linker DP-NHP. **A)** chemical structure of biotinylated SS-31. **B)** chemical structure of DP-NHP cross-linker. **C)** chemical structure for bSS-31 DP-stump ion which results from MS2 fragmentation of the PIR labile bonds of DP cross-linked bSS-31. Red lines with numbers indicate the bods which break to give rise to the major fragment ions observed in panel D. **D)** MS3 fragmentation pattern for bSS-31 DP stump ion with major fragment ions labeled. Bonds which fragment to give rise to these fragment ions are indicated in red in panel C. Ions at m/z 557.3 and m/z 366.2 result from loss of hydroxyl radical from fragments ions at m/z 574.3 and m/z 383.2 respectively.

Fig. S2 - Functional effects of bSS-31 on isolated mitochondria – A) Respiration in mitochondria isolated from young mouse hearts in the presence of bSS-31 (red) or vehicle control (blue). B) Respiration in mitochondria isolated from old mouse hearts in the presence of bSS-31 (red) or vehicle control (blue). C) H_2O_2 production per O2 consumption in old mitochondria isolated in the presence of bSS-31 (red) or vehicle control (blue). *P<0.05 using a paired t-test.

Fig. S3 - Amino acid composition of bSS-31 interaction interfaces – **A)** Bar plot indicating relative frequencies for the 20 amino acids in the MitoCarta2 database (red) and the amino acids comprising the bSS-31 interaction interface (residues within 5 angstroms of bSS-31 in docked models). Asterisks indicate a statistically significant difference (p<0.05) as calculated by the Composition Profiler tool. **B)** Output from Composition Profile comparing amino acid composition of the bSS-31 interaction interfaces to the MitoCarta2 database.

Table S1 – List of identified bSS-31 cross-linked peptides

Video S1 – Cross-link directed docked models for bSS-31 ADT1 interaction in the c-state (PDB: 2c3e) and m-state (PDB: 6gci). ADT is shown as red ribbon structures with the cross-linked residues K33 and K272 displayed as yellow space filled residues. Electrostatic interactions between D232-K33 and E265-K272 stabilize the c-state of ADT and are not present in the m-state. In the m-state docking results, the top scoring model without atomic clashes, suggests a potential charge interaction between D232 and the Arg of bSS-31.

Acknowledgments

References

1. Craven, L., et al., *Recent Advances in Mitochondrial Disease.* Annu Rev Genomics Hum Genet, 2017. **18**: p. 257-275.
2. El-Hattab, A.W., et al., *Therapies for mitochondrial diseases and current clinical trials.* Mol Genet Metab, 2017. **122**(3): p. 1-9.
3. Szeto, H.H. and A.V. Birk, *Serendipity and the discovery of novel compounds that restore mitochondrial plasticity.* Clin Pharmacol Ther, 2014. **96**(6): p. 672-83.
4. Szeto, H.H., *First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.* Br J Pharmacol, 2014. **171**(8): p. 2029-50.
5. Szeto, H.H., *Stealth Peptides Target Cellular Powerhouses to Fight Rare and Common Age-Related Diseases.* Protein Pept Lett, 2018. **25**(12): p. 1108-1123.
6. Pennington, E.R., et al., *The role of cardiolipin concentration and acyl chain composition on mitochondrial inner membrane molecular organization and function.* Biochim Biophys Acta Mol Cell Biol Lipids, 2019. **1864**(7): p. 1039-1052.
7. Paradies, G., et al., *Functional role of cardiolipin in mitochondrial bioenergetics.* Biochim Biophys Acta, 2014. **1837**(4): p. 408-17.
8. Ikon, N. and R.O. Ryan, *Cardiolipin and mitochondrial cristae organization.* Biochim Biophys Acta Biomembr, 2017. **1859**(6): p. 1156-1163.
9. Acehan, D., et al., *Cardiolipin affects the supramolecular organization of ATP synthase in mitochondria.* Biophys J, 2011. **100**(9): p. 2184-92.
10. Mehdipour, A.R. and G. Hummer, *Cardiolipin puts the seal on ATP synthase.* Proc Natl Acad Sci U S A, 2016. **113**(31): p. 8568-70.
11. Zhang, M., E. Mileykovskaya, and W. Dowhan, *Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane.* J Biol Chem, 2002. **277**(46): p. 43553-6.
12. Mileykovskaya, E. and W. Dowhan, *Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes.* Chem Phys Lipids, 2014. **179**: p. 42-8.
13. Arnarez, C., et al., *Evidence for cardiolipin binding sites on the membrane-exposed surface of the cytochrome bc1.* J Am Chem Soc, 2013. **135**(8): p. 3112-20.
14. Arnarez, C., S.J. Marrink, and X. Periole, *Identification of cardiolipin binding sites on cytochrome c oxidase at the entrance of proton channels.* Sci Rep, 2013. **3**: p. 1263.
15. Arnarez, C., S.J. Marrink, and X. Periole, *Molecular mechanism of cardiolipin-mediated assembly of respiratory chain supercomplexes.* Chem Sci, 2016. **7**(7): p. 4435-4443.
16. Hoffmann, B., et al., *The reconstituted ADP/ATP carrier activity has an absolute requirement for cardiolipin as shown in cysteine mutants.* J Biol Chem, 1994. **269**(3): p. 1940-4.
17. Szeto, H.H. and S. Liu, *Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote tissue regeneration during aging.* Arch Biochem Biophys, 2018. **660**: p. 137-148.
18. Birk, A.V., et al., *The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.* J Am Soc Nephrol, 2013. **24**(8): p. 1250-61.
19. Birk, A.V., et al., *Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis.* Br J Pharmacol, 2014. **171**(8): p. 2017-28.
20. Arora, B., et al., *Chemical Crosslinking: Role in Protein and Peptide Science.* Curr Protein Pept Sci, 2017. **18**(9): p. 946-955.
21. Piotrowski, C. and A. Sinz, *Structural Investigation of Proteins and Protein Complexes by Chemical Cross-Linking/Mass Spectrometry.* Adv Exp Med Biol, 2018. **1105**: p. 101-121.

22. Sinz, A., *Cross-Linking/Mass Spectrometry for Studying Protein Structures and Protein-Protein Interactions: Where Are We Now and Where Should We Go from Here?* Angew Chem Int Ed Engl, 2018. **57**(22): p. 6390-6396.

23. Chavez, J.D. and J.E. Bruce, *Chemical cross-linking with mass spectrometry: a tool for systems structural biology.* Curr Opin Chem Biol, 2019. **48**: p. 8-18.

24. Chavez, J.D., et al., *Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells.* PLoS One, 2011. **6**(5): p. e19892.

25. Chavez, J.D., et al., *Protein interactions, post-translational modifications and topologies in human cells.* Mol Cell Proteomics, 2013. **12**(5): p. 1451-67.

26. Chavez, J.D., et al., *In Vivo Conformational Dynamics of Hsp90 and Its Interactors.* Cell Chem Biol, 2016. **23**(6): p. 716-26.

27. Schweppe, D.K., et al., *Mitochondrial protein interactome elucidated by chemical cross-linking mass spectrometry.* Proc Natl Acad Sci U S A, 2017. **114**(7): p. 1732-1737.

28. Chavez, J.D., et al., *Chemical Crosslinking Mass Spectrometry Analysis of Protein Conformations and Supercomplexes in Heart Tissue.* Cell Syst, 2018. **6**(1): p. 136-141 e5.

29. Anderson, E.J., et al., *Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans.* J Clin Invest, 2009. **119**(3): p. 573-81.

30. Siegel, M.P., et al., *Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.* Aging Cell, 2013. **12**(5): p. 763-71.

31. Zhao, K., et al., *Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury.* J Biol Chem, 2004. **279**(33): p. 34682-90.

32. Campbell, M.D., et al., *Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice.* Free Radic Biol Med, 2018. **134**: p. 268-281.

33. Weisbrod, C.R., et al., *In vivo protein interaction network identified with a novel real-time cross-linked peptide identification strategy.* J Proteome Res, 2013. **12**(4): p. 1569-79.

34. Mohr, J.P., et al., *Mango: A General Tool for Collision Induced Dissociation-Cleavable Cross-Linked Peptide Identification.* Anal Chem, 2018. **90**(10): p. 6028-6034.

35. Schneidman-Duhovny, D., et al., *PatchDock and SymmDock: servers for rigid and symmetric docking.* Nucleic Acids Res, 2005. **33**(Web Server issue): p. W363-7.

36. McWilliam, H., et al., *Analysis Tool Web Services from the EMBL-EBI.* Nucleic Acids Res, 2013. **41**(Web Server issue): p. W597-600.

37. Keller, A., et al., *Tools for 3D Interactome Visualization.* J Proteome Res, 2019. **18**(2): p. 753-758.

38. Vacic, V., et al., *Composition Profiler: a tool for discovery and visualization of amino acid composition differences.* BMC Bioinformatics, 2007. **8**: p. 211.

39. Calvo, S.E., K.R. Clauser, and V.K. Mootha, *MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins.* Nucleic Acids Res, 2016. **44**(D1): p. D1251-7.

40. Esser, L., et al., *Crystallographic studies of quinol oxidation site inhibitors: a modified classification of inhibitors for the cytochrome bc(1) complex.* J Mol Biol, 2004. **341**(1): p. 281-302.

41. Cramer, W.A., S.S. Hasan, and E. Yamashita, *The Q cycle of cytochrome bc complexes: a structure perspective.* Biochim Biophys Acta, 2011. **1807**(7): p. 788-802.

42. Letts, J.A. and L.A. Sazanov, *Clarifying the supercomplex: the higher-order organization of the mitochondrial electron transport chain.* Nat Struct Mol Biol, 2017. **24**(10): p. 800-808.

43. Ndi, M., et al., *Biogenesis of the bc1 Complex of the Mitochondrial Respiratory Chain.* J Mol Biol, 2018. **430**(21): p. 3892-3905.

44. Solmaz, S.R. and C. Hunte, *Structure of complex III with bound cytochrome c in reduced state and definition of a minimal core interface for electron transfer.* J Biol Chem, 2008. **283**(25): p. 17542-9.

45.   Zong, S., et al., *Structure of the intact 14-subunit human cytochrome c oxidase.* Cell Res, 2018. **28**(10): p. 1026-1034.

46.   Pitceathly, R.D.S. and J.W. Taanman, *NDUFA4 (Renamed COXFA4) Is a Cytochrome-c Oxidase Subunit.* Trends Endocrinol Metab, 2018. **29**(7): p. 452-454.

47.   Robinson, N.C., *Functional binding of cardiolipin to cytochrome c oxidase.* J Bioenerg Biomembr, 1993. **25**(2): p. 153-63.

48.   Malkamaki, A. and V. Sharma, *Atomistic insights into cardiolipin binding sites of cytochrome c oxidase.* Biochim Biophys Acta Bioenerg, 2019. **1860**(3): p. 224-232.

49.   Blum, T.B., et al., *Dimers of mitochondrial ATP synthase induce membrane curvature and self-assemble into rows.* Proc Natl Acad Sci U S A, 2019.

50.   Eble, K.S., et al., *Tightly associated cardiolipin in the bovine heart mitochondrial ATP synthase as analyzed by 31P nuclear magnetic resonance spectroscopy.* J Biol Chem, 1990. **265**(32): p. 19434-40.

51.   Duncan, A.L., A.J. Robinson, and J.E. Walker, *Cardiolipin binds selectively but transiently to conserved lysine residues in the rotor of metazoan ATP synthases.* Proc Natl Acad Sci U S A, 2016. **113**(31): p. 8687-92.

52.   Strauss, M., et al., *Dimer ribbons of ATP synthase shape the inner mitochondrial membrane.* EMBO J, 2008. **27**(7): p. 1154-60.

53.   Davies, K.M., et al., *Structure of the yeast F1Fo-ATP synthase dimer and its role in shaping the mitochondrial cristae.* Proc Natl Acad Sci U S A, 2012. **109**(34): p. 13602-7.

54.   Hahn, A., et al., *Structure of a Complete ATP Synthase Dimer Reveals the Molecular Basis of Inner Mitochondrial Membrane Morphology.* Mol Cell, 2016. **63**(3): p. 445-56.

55.   Giorgio, V., et al., *Dimers of mitochondrial ATP synthase form the permeability transition pore.* Proc Natl Acad Sci U S A, 2013. **110**(15): p. 5887-92.

56.   Dzeja, P.P. and A. Terzic, *Phosphotransfer networks and cellular energetics.* J Exp Biol, 2003. **206**(Pt 12): p. 2039-47.

57.   Schlattner, U., et al., *Mitochondrial kinases and their molecular interaction with cardiolipin.* Biochim Biophys Acta, 2009. **1788**(10): p. 2032-47.

58.   Schlattner, U., et al., *C-terminal lysines determine phospholipid interaction of sarcomeric mitochondrial creatine kinase.* J Biol Chem, 2004. **279**(23): p. 24334-42.

59.   Fritz-Wolf, K., et al., *Structure of mitochondrial creatine kinase.* Nature, 1996. **381**(6580): p. 341-5.

60.   Karo, J., P. Peterson, and M. Vendelin, *Molecular dynamics simulations of creatine kinase and adenine nucleotide translocase in mitochondrial membrane patch.* J Biol Chem, 2012. **287**(10): p. 7467-76.

61.   Kunji, E.R., et al., *The transport mechanism of the mitochondrial ADP/ATP carrier.* Biochim Biophys Acta, 2016. **1863**(10): p. 2379-93.

62.   Pebay-Peyroula, E., et al., *Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside.* Nature, 2003. **426**(6962): p. 39-44.

63.   Ruprecht, J.J., et al., *The Molecular Mechanism of Transport by the Mitochondrial ADP/ATP Carrier.* Cell, 2019. **176**(3): p. 435-447 e15.

64.   Bertholet, A.M., et al., *H+ transport is an integral function of the mitochondrial ADP/ATP carrier.* Nature, 2019. **571**(7766): p. 515-520.

65.   Liang, K., et al., *Cryo-EM structure of human mitochondrial trifunctional protein.* Proc Natl Acad Sci U S A, 2018. **115**(27): p. 7039-7044.

66.   Xia, C., et al., *Crystal structure of human mitochondrial trifunctional protein, a fatty acid beta-oxidation metabolon.* Proc Natl Acad Sci U S A, 2019. **116**(13): p. 6069-6074.

67. Ishikawa, M., et al., *Structural basis for channelling mechanism of a fatty acid beta-oxidation multienzyme complex.* EMBO J, 2004. **23**(14): p. 2745-54.

68. Venkatesan, R. and R.K. Wierenga, *Structure of mycobacterial beta-oxidation trifunctional enzyme reveals its altered assembly and putative substrate channeling pathway.* ACS Chem Biol, 2013. **8**(5): p. 1063-73.

69. Taylor, W.A., et al., *Human trifunctional protein alpha links cardiolipin remodeling to beta-oxidation.* PLoS One, 2012. **7**(11): p. e48628.

70. Huergo, L.F. and R. Dixon, *The Emergence of 2-Oxoglutarate as a Master Regulator Metabolite.* Microbiol Mol Biol Rev, 2015. **79**(4): p. 419-35.

71. Chin, R.M., et al., *The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR.* Nature, 2014. **510**(7505): p. 397-401.

72. Fuhrmann, D.C. and B. Brune, *Mitochondrial composition and function under the control of hypoxia.* Redox Biol, 2017. **12**: p. 208-215.

73. Abboud, M.I., et al., *2-Oxoglutarate regulates binding of hydroxylated hypoxia-inducible factor to prolyl hydroxylase domain 2.* Chem Commun (Camb), 2018. **54**(25): p. 3130-3133.

74. Reitman, Z.J. and H. Yan, *Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.* J Natl Cancer Inst, 2010. **102**(13): p. 932-41.

75. Jo, S.H., et al., *Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase.* J Biol Chem, 2001. **276**(19): p. 16168-76.

76. Suga, K., et al., *Liposomes modified with cardiolipin can act as a platform to regulate the potential flux of NADP(+)-dependent isocitrate dehydrogenase.* Metab Eng Commun, 2016. **3**: p. 8-14.

77. Xu, Y., et al., *Studies on the regulatory mechanism of isocitrate dehydrogenase 2 using acetylation mimics.* Scientific Reports, 2017. **7**(1): p. 9785.

78. Rex Sheu, K.-F. and J.P. Blass, *The α-Ketoglutarate Dehydrogenase Complex.* Annals of the New York Academy of Sciences, 1999. **893**(1): p. 61-78.

79. Quinlan, C.L., et al., *The 2-oxoacid dehydrogenase complexes in mitochondria can produce superoxide/hydrogen peroxide at much higher rates than complex I.* J Biol Chem, 2014. **289**(12): p. 8312-25.

80. van Gestel, R.A., et al., *The influence of the acyl chain composition of cardiolipin on the stability of mitochondrial complexes; an unexpected effect of cardiolipin in alpha-ketoglutarate dehydrogenase and prohibitin complexes.* J Proteomics, 2010. **73**(4): p. 806-14.

81. Jiang, X., et al., *Recombinant expression, purification and crystallographic studies of the mature form of human mitochondrial aspartate aminotransferase.* Biosci Trends, 2016. **10**(1): p. 79-84.

82. Bradbury, M.W., et al., *Molecular modeling and functional confirmation of a predicted fatty acid binding site of mitochondrial aspartate aminotransferase.* J Mol Biol, 2011. **412**(3): p. 412-22.

83. Teller, J.K., L.A. Fahien, and E. Valdivia, *Interactions among mitochondrial aspartate aminotransferase, malate dehydrogenase, and the inner mitochondrial membrane from heart, hepatoma, and liver.* J Biol Chem, 1990. **265**(32): p. 19486-94.

84. Donate, F., et al., *Interaction of the precursor to mitochondrial aspartate aminotransferase and its presequence peptide with model membranes.* J Biol Chem, 2000. **275**(44): p. 34147-56.

85. Keller, A., et al., *A uniform proteomics MS/MS analysis platform utilizing open XML file formats.* Mol Syst Biol, 2005. **1**: p. 2005 0017.

86. Eng, J.K., T.A. Jahan, and M.R. Hoopmann, *Comet: an open-source MS/MS sequence database search tool.* Proteomics, 2013. **13**(1): p. 22-4.

Mice CB6F1 → heart → mitochondria → SS-31 → Cross-link → Protein extraction

PIR

Respiration/ROS measurements

O_2 → H_2O

Interactome analysis

SS-31

LC-MS ← enrichment ← SS-31 ← PIR

Structural analysis

digestion

PIR

SS-31

Figure 1

Figure 2

K199

bSS-31

bSS-31

K83

bSS-31

K74

K480

K506

bSS-31

QCR2

ATPB

ATPA

M

CL

NDUA4

CL

CL binding
residues

IMM

IMS

QCR6

Figure 3

A)

OM

IMS

IM

K230

B)

IMS

IM

M

K33

K272

90°

CATR-locked ADT
c-state

IMS

IM

M

K33

K272

90°

K272

K33

BKA-locked ADT
m-state

Figure 4

Figure 5

A

IDHP_b   IDHP_a

K180_a

K272_b

bSS-31

K360_a

2-OG
CO_2
NADPH

isocitrate
NADP^+

B

K180_a   K129_a
K256_b
K133_a
E120_a   K127_a
E124_a
D314_a   E125_a
D291_a   D56_a
D29_a
D318_a
E286_b
E57_a
bSS-31
D414_a
K360_a

C

2-OG   TPP

SS-31

E1

CO_2

succinyl-
TPP

SH—lip   E2
S-succinyl

CoA

succinyl-CoA

S-S
lip

FADH_2

E3

NAD^+

NADH

SS-31

lip   SH

lip   SH
SH

FAD

D

AATM_a   AATM_b

K159_a

bSS-31

oxaloacetate
glutamate

2-OG
aspartate

Figure 6

A

bSS-31

Biotin-D-Arg-dimethylTyr-Lys-Phe-NH$_2$

Monoisotopic Mass: 865.463263 Da

B

DP-NHP

NH2-Lys-(Pro-Asp-Succ-NHP)$_2$

Monoisotopic Mass: 1059.345771 Da

C

383.2

574.3

866.5

947.5

965.5

1019.5

bSS-31 DP-stump ion

Monoisotopic Mass: 1063.502962 Da

Fig. S1

D

MS3 fragmentation spectrum for 1063.50$^+$

Relative Abundance

100

0

$[M-C_2O_3]^+$
991.5

$[M-C_4H_2O_3]^+$
965.5

$[M-CO_2]^+$
1019.5

$[M-Asp]^+$
947.5

$[M-Asp-Succ]^+$
866.5

-OH
366.2

383.2

-OH
557.3

**574.3**

400   600   800   1000

m/z

A Young Mitochondrial Respiration

B Old Mitochondrial Respiration

C Mitochondrial Respiration Efficiency

Fig. S2

A

Relative amino acid frequencies for bSS-31 interaction interface at 5Å

B

COMPOSITION PROFILER

Ala	Not significant.	P-value=0.625319 (>0.050000)
Arg	Not significant.	P-value=0.130040 (>0.050000)
Asn	Not significant.	P-value=0.967645 (>0.050000)
Asp	⬆Enriched.	P-value=0.000151 (≤0.050000)
Cys	Not significant.	P-value=0.452208 (>0.050000)
Gln	Not significant.	P-value=0.852845 (>0.050000)
Glu	Not significant.	P-value=0.837160 (>0.050000)
Gly	Not significant.	P-value=0.299125 (>0.050000)
His	Not significant.	P-value=0.158045 (>0.050000)
Ile	Not significant.	P-value=0.396237 (>0.050000)
Leu	⬇Depleted.	P-value=0.018157 (≤0.050000)
Lys	Not significant.	P-value=0.514830 (>0.050000)
Met	Not significant.	P-value=0.947528 (>0.050000)
Phe	Not significant.	P-value=0.351050 (>0.050000)
Pro	Not significant.	P-value=0.091603 (>0.050000)
Ser	Not significant.	P-value=0.866523 (>0.050000)
Thr	⬆Enriched.	P-value=0.040943 (≤0.050000)
Trp	Not significant.	P-value=0.411683 (>0.050000)
Tyr	Not significant.	P-value=0.244195 (>0.050000)
Val	Not significant.	P-value=0.508747 (>0.050000)

Fig. S3